ADVFN ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Premium IconPremium Help Menu
S&P 500
6,263.70
0.32%
Dow Jones
44,254.78
0.53%
US Dollar vs MXN
18.7207
-0.45%
Brent Oil
68.14
-0.29%
Bitcoin
118,722.92
0.79%
Pepperstone
AdvertisementAdvertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Sarepta Therapeutics Inc New (SRPT) Cotización

Sarepta Therapeutics Inc New

Sarepta Therapeutics Inc New (SRPT)

NASDAQ
18.38
0.17
(0.93%)
Al cierre: 16 Julio 3:00PM
15 min retrasado - Mejora a Tiempo Real
24.6501
6.27
( 34.11% )
Fuera de horario: 6:36PM
15 min retrasado - Mejora a Tiempo Real

Sarepta Therapeutics Inc New (SRPT) Cotización

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
24.6501
( 35.37% )
Postura de Compra
24.66
Postura de Venta
24.75
Volume Operado de la Acción
12,866,089
17.84 Rango del Día 18.54
16.88 Rango de 52 semanas 153.30
Capitalización de Mercado [m]
2.423B
Precio Anterior
18.21
Precio de Apertura
18.30
Hora
20
@
24.74
Última hora de negociación
18:36:17
Volumen financiero
US$ 234,265,337
Precio Promedio Ponderado
18.208
Volumen promedio (3 m)
5,703,447
Acciones en circulación
98,277,032
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
7.69
Beneficio por acción (BPA)
2.39
turnover
1.9B
Beneficio neto
235.24M

Acerca de Sarepta Therapeutics Inc New

Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for deve... Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.sarepta.com
Sede
Wilmington, Delaware, USA
Fundado
-
Sarepta Therapeutics Inc New is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SRPT. The last closing price for Sarepta Therapeutics was US$18.21. Over the last year, Sarepta Therapeutics shares have traded in a share price range of US$ 16.88 to US$ 153.30.

Sarepta Therapeutics currently has 98,277,032 shares in issue. The market capitalisation of Sarepta Therapeutics is US$1.79 billion. Sarepta Therapeutics has a price to earnings ratio (PE ratio) of 7.69.

Flujo de Opciones Sarepta Therapeutics (SRPT)

Ver flujo de opciones completo

Flujo General

Optimista

Prima Neta

43k

Calls / Puts

100.00%

Comp. / Vent.

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

SRPT Últimas noticias

Más noticias

Form 8-K - Current report
Edgar (US Regulatory)
4 horas hace
SRPT (0.93%)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
15.750130.423809523818.929.3217.95378992818.84170225CS
43.485116.46633593221.16529.3216.88569247118.57886877CS
12-36.9999-60.016058394261.6564.816.88570344730.40514757CS
26-94.6999-79.3463762044119.35120.0516.88368614142.75621503CS
52-127.4599-83.7945565709152.11153.316.88230311960.9301978CS
156-59.0699-70.5564978583.72173.116.88163971891.62188042CS
260-142.7699-85.276490264167.42181.8316.88139397891.85220904CS

SRPT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Sarepta Therapeutics?
El precio actual de las acciones de Sarepta Therapeutics es US$ 24.6501
¿Cuántas acciones de Sarepta Therapeutics están en circulación?
Sarepta Therapeutics tiene 98,277,032 acciones en circulación
¿Cuál es la capitalización de mercado de Sarepta Therapeutics?
La capitalización de mercado de Sarepta Therapeutics es USD 1.79B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Sarepta Therapeutics?
Sarepta Therapeutics ha negociado en un rango de US$ 16.88 a US$ 153.30 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Sarepta Therapeutics?
El ratio precio/beneficio de Sarepta Therapeutics es 7.69
¿Cuál es el ratio de efectivo a ventas de Sarepta Therapeutics?
El ratio de efectivo a ventas de Sarepta Therapeutics es 0.95
¿Cuál es la moneda de reporte de Sarepta Therapeutics?
Sarepta Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Sarepta Therapeutics?
El último ingresos anual de Sarepta Therapeutics es USD 1.9B
¿Cuál es el último beneficio anual de Sarepta Therapeutics?
El último beneficio anual de Sarepta Therapeutics es USD 235.24M
¿Cuál es la dirección registrada de Sarepta Therapeutics?
La dirección registrada de Sarepta Therapeutics es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Sarepta Therapeutics?
La dirección del sitio web de Sarepta Therapeutics es www.sarepta.com
¿En qué sector industrial opera Sarepta Therapeutics?
Sarepta Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
XXII22nd Century Group Inc
US$ 7.13
(55.68%)
1.25M
SRPTSarepta Therapeutics Inc New
US$ 24.58
(33.73%)
9.93M
DPRODraganfly Inc
US$ 6.82
(31.66%)
4.14M
ABVEAbove Food Ingredients Inc
US$ 2.06
(22.62%)
3.54M
ZBAIATIF Holdings Ltd
US$ 0.781
(17.98%)
3.87M
CGBSCrown LNG Holdings Ltd
US$ 0.0152
(-59.03%)
121.64M
YHCLQR House Inc
US$ 8.75
(-18.45%)
4.11M
IMRNImmuron Ltd
US$ 1.60
(-14.44%)
6.39k
ZVSAZyVersa Therapeutics Inc
US$ 0.2742
(-11.92%)
3.36M
GAMEGameSquare Holdings Inc
US$ 2.05
(-11.26%)
4.59M
CGBSCrown LNG Holdings Ltd
US$ 0.0152
(-59.03%)
121.64M
OPENOpendoor Technologies Inc
US$ 1.56
(4.70%)
26.52M
BLMZBloomZ Inc
US$ 0.2054
(4.00%)
9.98M
SRPTSarepta Therapeutics Inc New
US$ 24.58
(33.73%)
9.93M
GTIGraphjet Technology
US$ 0.1098
(5.58%)
9.82M

SRPT Discussion

Ver más
johnhancoque johnhancoque 6 días hace
How many kids have died here?
👍️0
Zilla Zilla 3 semanas hace
17 makes even less sense
👍️0
Monroe1 Monroe1 3 semanas hace
uh oh legal eagles lurking
👍️0
tw0122 tw0122 4 semanas hace
Ride it back to $25
👍️0
Zilla Zilla 1 mes hace
36.36 Doesn't make sense but it is what it is at the moment...
👍️0
theswordman theswordman 2 meses hace
CBER
👍️0
north40000 north40000 2 meses hace
SRPT trading at $35-$36/share.......what's great about that?   Sorry about market value loss. I sold our shares months ago at a profit/share that was far less than it used to be.
👍️0
Schmiggins Schmiggins 2 meses hace
New CDER guy will actually be great for Sarepta.
In addition to allowing us to buy back shares even cheaper today!

He has bashed Elevidys and Sarepta in the past - the price and Mark's approval.

But now he needs to show that he's even-handed towards us. And next up or him and us will be the LMGD drugs which are clean cut as far as proof of concept and efficacy, so it'll be an easy win for him and us.
👍️0
axelvento axelvento 4 meses hace
Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies


https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-death-liver-failure/742765/


down
👍️0
Monksdream Monksdream 11 meses hace
SRPT 10Q due AUGUST5
👍️0
Awl416 Awl416 1 año hace
Honeywell Acquires CAES Systems for $1.9 Billion, Sarepta Therapeutics Surges 34%, Gilead Continues Gains
👍️0
north40000 north40000 1 año hace
SRPT obtains an expanded approval by FDA for treatment of DMD. Share price is $174, +~ 56% on news.
👍️0
BottomBounce BottomBounce 2 años hace
$SRPT Total Debt (mrq) $1.38B back to $.50
👍️0
north40000 north40000 2 años hace
Readers might also check CPRX news release AH last Thursday, re FDA approval of a DMD drug for which CPRX has an exclusive license to market/sell in North America. CPRX plans introduction in early 2024.
👍️0
Schmiggins Schmiggins 2 años hace
Thanks. Like Barron's here, I speculated a while ago that if this trial succeeds as the company has long said it would - and we finally reach that happy $200 shore - I do think it may energize the XBI Biotech index ... which it looks like hasn't made any progress since 2015!!

It's like people think the science here is bogus, dead in the water. Well, it's not. And hopefully Sarepta is on the verge of proving that in the next few weeks.
👍️0
abew4me abew4me 2 años hace
Hi Joseph...and thanks for posting all of this information.

My curiosity of gene therapy doesn't really have anything to do with Sarepta other than to inquire if it breaks the double-strand in the DNA when it treats its patients?

The reason I ask that question is based on another company called BEAM. I don't want to go into detail here because it wouldn't be fair to the investors on this board. Please go to the BEAM board for more details.

Thanks

abe
👍️ 2
Joseph_K Joseph_K 2 años hace
abew4me (and unknown ghosts of the iHub Sarepta message board): Insurance funding for Elevidys has been a stock market issue for Sarepta. My (limited, but I think effective) due diligence in this has been in finding and keeping up with the Facebook page of Little Hercules Foundation. It has, I think, been assiduously following the issue, telling caretakers about both the insurers who have agreed to provide coverage (and any conditions thereon) and those denying coverage (with regard to which it tries to organize pressure campaigns). You'll have to review the entries yourself, but my (neither scientific nor well-organized) survey of them I felt showed that the considerable majority of insurers were providing coverage (per the rather restrictive current FDA label). If you look through those entries and conclude otherwise, please post your thoughts here. Once I did that bit of DD, I upped my investment.

You (abew) also asked about my DD on genomics. I don't remember what I posted. I do believe gene therapy will make many other cures obsolete. (I listen to a lot of science podcasts and read science books and articles some, too.) I think there was a Rett Syndrome genetic therapy in Phase 1, but all I recall doing was calculating how many years before it could possibly receive FDA approval.
👍️ 1
Joseph_K Joseph_K 2 años hace
Hi, Sarepta iHub ghost town. From Barron's:

The upside/downside trade-off for Sarepta Therapeutics [SPRT] is attractive going into the end of the year. We are coming up on results of what could be a confirmatory study of its gene-therapy drug for Duchenne muscular dystrophy. This could be a seminal moment for what has been a controversial stock, and provide a boost, albeit moderate, for the biotech space as a whole, especially
as the index is trending toward multiyear lows.
There appears to be two ways to win with Sarepta. One way is that the Phase 3 study shows an improvement for patients, even if very modest, but enough to illustrate a trend. This represents the base case or perhaps the most likely outcome, given the patient
population, but would also ensure that the gene therapy, which has already been conditionally approved by the Food and Drug
Administration (pending this trial), remains on the market. Best case, the trial demonstrates a statistically significant difference in the drug's favor versus the placebo, and Sarepta might address a larger market, including many patients who would otherwise not have access to the therapy. I believe that a positive trial would move the stock, now around $120, to or above $200 a share. If the drug fails to show even a modest benefit and investors remove gene therapy from models, a worst-case outcome could result in a stock price of around $60, depending on other assumptions. In the biotech sector, we are used to volatility.
👍️ 1
Schmiggins Schmiggins 2 años hace
Currently it's approved for only ages 4 and 5. CEO said there are 700 now in that age group in the US....The usual number of DMD kids born each year is 1 in 3,500. Check that with DMD organizations rather than what somebody plugged into some pretend "AI" toy. When approved for all ages you'd be talking 7,000 to 10,000. After they are all dosed (if that were to happen), then it reverts to maybe 350 a year. By that time it would be worldwide in the hands of Roche. I just saw a global number of 100,000. It is the most common rare disease.

Analysts and biotech journalists and scientists are the only ones who care about the drug and Sarepta and talk about it now that it's a success. its message boards are a barren desert where once it was an Amazonian rain forest.

I'm not sure how an individual investor can learn about the company's science at this point. Study the company's website for that. It's all there.

In a way, the fun (drama) is just about over. Just need the trial data in a few months to be good. The share price it seems to me will be under control of the big boys wanting to top off their positions before that data comes out. So it's a good time to do the same. After success in that trial is confirmed we'll be another Regeneron as far a stock goes. Possible much better. We should have as many diseases we can treat as it looks like Anavex will have someday.
👍️ 1
Joseph_K Joseph_K 2 años hace
I was pleased with yesterday's earnings and conference call. It also made me realize how much I know about blarcamesine! That is, I couldn't follow any of the discussion about Sarepta's research and trials in the call. But the expectation of broad insurance coverage and drug administration of the gene therapy before year's end has me optimistic enough to hold on to my now not-insubstantial Sarepta holdings through at least the first 2024 earnings report (assuming things appear to be proceeding as indicated yesterday).

Your calculation on Investor Village for administrations of the gene therapy will obviously have to slow down as, from what I gathered from the call, only 400 children per year are diagnosed with Duchenne. (Hmm, I just asked Google Bard, which replied, "According to the CDC, about 1 in 5,000 live male births in the United States are affected by Duchenne muscular dystrophy (DMD). This means that about 200 new cases of DMD are diagnosed in the US each year.") I guess, OTOH, it's a big world out there to expand into, though most of it will not be coughing up millions of dollars per child. (I hope there's some sort of charitable solution for them over time. What a horrible disease.)

Also, it was interesting, for a change, compared to Anavex, to hear a conference call with all these questions from analysts who work for companies I'd already heard of!
👍️0
Schmiggins Schmiggins 2 años hace
Hellooooo.....I hear an echo in here .....

Sarepta will be fine. I expect the strange people at the FDA to take another look at us in September/October and some are suggesting they will end the trial early (it will be finished in effect at that point anyway) due to unambiguous success seen ... and approve the drug for all ages - as they apparently told our CEO a few months ago would be "the label" upon any formal approval - which was expected to be early next year or late this year. But, as i say, some expect they take an October re-look at the trial and accept it's success and expand the label then and there. That will bring the stock to 200 more or less. That will unleash the dam and we can move on to other things, finally. Check out the Investor village board for more of my ranting and raving if you dare. Otherwise, maybe you can explore any other Sarepta boards - stocktwits? reddit? for me too .... and if you find one that's wiggling a bit more than this one (!) or IV, let me know...with links. (I'm pretty lame. I had a hard time finding this one again just now!) Thanks and all should be well now with Sarepta, finally.

Maybe there's someone here who can correct or expand on my info for newbie Mr. K's benefit. And to exercise your fingers a bit as well!
👍️ 1
Joseph_K Joseph_K 2 años hace
Hi, Schmiggins! Any thoughts on where Sarepta is heading? Your thoughts on staying invested or not? I bought in a week ago after the fall following the NDA approval, stupidly catching a falling knife, but so far retrospectively okay, at 111+ and 109+. I'm ahead for now, but ... (By the way, I have much less SRPT than AVXL. I've been in Anavex since mid-2021. I'm considerably underwater on Anavex, having doubled my holdings pre-market the morning after the CTAD conference in December 2022. AVXL shot up that morning then slid, slid, slid.)
👍️0
XWAVXALMIMAN XWAVXALMIMAN 2 años hace
Congrats to longs. Monday should be a good day. Anyone following Capricor - CAPR
CEO said CAPR drug helps cardiac election fraction and helps upper limb function in DMD. She says combination with Sarepta’s drug could be better than either alone. Maybe Sarepta should by Capricor?
👍️0
sorkin sorkin 3 años hace
Go SRPT , buyout AMLX
👍️0
TheFinalCD TheFinalCD 3 años hace
looking to get some $SRPT call options
👍️0
girlfriend girlfriend 3 años hace
Thankful I didn't sell all my shares.
👍️0
Atown62 Atown62 3 años hace
Good stuff
👍️0
girlfriend girlfriend 3 años hace
Indeed. Wish I had more shares but this market is freaky!
👍️0
Atown62 Atown62 3 años hace
Trend is UP…
👍️0
Atown62 Atown62 3 años hace
👍️0
girlfriend girlfriend 3 años hace
Thank you!
👍️0
Atown62 Atown62 3 años hace
https://musculardystrophynews.com/2022/03/21/mda-2022-dmd-boys-improved-walking-motor-function-3-years-after-srp-9001-gene-therapy/
👍️0
Atown62 Atown62 3 años hace
Cheers!
👍️0
girlfriend girlfriend 3 años hace
I have a core position in SRPT in an IRA. Been fun trading the high 60’s to 80ish channel over past year or so.

Good Luck about to board a plane back to the States!
👍️0
Atown62 Atown62 3 años hace
My large positions are this and $SOF.I @ 11.20
👍️0
girlfriend girlfriend 3 años hace
Yes it has. Especially considering biotech and therapeutics are out of favour for awhile.

👍️0
Atown62 Atown62 3 años hace
It’s been a decent trade
👍️0
girlfriend girlfriend 3 años hace
I was early buying these 68's but....added some 61's and 63's so actually am ahead right now. Nice comeback for SRPT today with the markets!
👍️0
girlfriend girlfriend 3 años hace
Bought a few more shares just now in low 68's.

Good Luck!
👍️0
Atown62 Atown62 4 años hace
You too
👍️0
girlfriend girlfriend 4 años hace
Have very few shares left….good luck to us.
👍️0
Atown62 Atown62 4 años hace
Lightened the load but Monday is a big news update regarding 9001-102 with JP
Morgan conference at 10:30AM


👍️0
Atown62 Atown62 4 años hace
This thing is just gonna chill at 80-85 until DI gets his hand outta his ass and updates 102 in January
👍️0
Atown62 Atown62 4 años hace
Same with $M

I’m anticipating a great 2022 especially with all the insider buying and anticipated news in January
👍️0
girlfriend girlfriend 4 años hace
I have been holding a smallish core position in an IRA and trading 100 size lots when appropriate. I usually let some go on good up days.

Otherwise.....be careful out there.

M...did let go of my entire position.
👍️0
Atown62 Atown62 4 años hace
I rebought my entire position and some with a now $79 average.
👍️0
Atown62 Atown62 4 años hace
Back in!
👍️0
Myth Myth 4 años hace
SRPT....

POS...
👍️0
Atown62 Atown62 4 años hace
I was waiting for 120.

And sold for a massive profit that was told to be “dead money”

It’s funny, cause atown is right again!

Srpt
👍️0
Myth Myth 4 años hace
I'm waiting for 120.00

the dilution news was GREAT !!
👍️0

Su Consulta Reciente

NASDAQ
SRPT
Sarepta Therapeutics
Delayed Upgrade Clock
ADVFN
México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN Ltd - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios